Real‐world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia
American Journal of Hematology · 2023-08 · 98 (8) · 1254-1264
DOI: 10.1002/ajh.26991 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Hematology, online erschienen am 19.06.2023. Verfasst von Andrew H Matthews und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Cytarabine, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Intensive chemotherapy with cytarabine and anthracycline (7&3) remains the standard therapy for patients medically fit for induction, but the assessment of fitness remains controversial. Venetoclax and hypomethylating agent (ven/HMA) combination therapy has improved outcomes in unfit patients but no prospective study has assessed ven/HMA versus 7&3 as initial therapy in older, fit patients. Given no studies and expectation of ven/HMA use in patients outside of trial criteria, we evaluated retrospective outcomes among newly diagnosed patients. A nationwide electronic health record (EHR)‐derived database and the University of Pennsylvania EHR identified 312 patients receiving 7&3 and 488 receiving ven/HMA who were 60–75 years old without history of organ failure. Ven/HMA patients were older and more likely to have secondary AML, adverse cytogenetics, and adverse mutations. Median overall survival (OS) for patients receiving intensive chemotherapy was 22 versus 10 months for ven/HMA (HR 0.53, 95% CI 0.40–0.60). Controlling for measured baseline characteristic imbalances reduced survival advantage by half (HR 0.71, 95% CI 0.53–0.94). A sub‐group of patients with equipoise, likelihood at least 30%–70% of receiving either treatment, had similar OS outcomes (HR 1.10, 95% CI 0.75–1.6). Regarding safety outcomes, 60‐day mortality was higher for ven/HMA (15% vs. 6% at 60 days) despite higher documented infections and febrile neutropenia for 7&3. In this multicenter real‐word dataset, patients selected for intensive chemotherapy had superior OS but a large group had similar outcomes with ven/HMA. Prospective randomized studies, controlling for both measured and unmeasured confounders, must confirm this outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Andrew H Matthews, Keith W Pratz
Förderung
- NHLBI NIH HHS
Zitieren
APA
Matthews, A. H., Perl, A. E., Luger, S. M., Gill, S. I., Lai, C., Porter, D. L., Skuli, S., Bruno, X. J., Carroll, M. P., Freyer, C. W., Carulli, A., Babushok, D. V., Frey, N. V., Hexner, E. O., Martin, M. E., McCurdy, S. R., Stadtmauer, E. A., Loren, A. W., Paralkar, V. R., …, & Pratz, K. W. (2023). Real‐world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia. American Journal of Hematology, 98(8), 1254-1264. https://doi.org/10.1002/ajh.26991
Vancouver
Matthews AH, Perl AE, Luger SM, Gill SI, Lai C, Porter DL, et al. Real‐world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia. American Journal of Hematology. 2023;98(8):1254-1264. doi:10.1002/ajh.26991
BibTeX
@article{Matthews2023,
author = {Matthews, Andrew H and Perl, Alexander E and Luger, Selina M and Gill, Saar I and Lai, Catherine and Porter, David L and Skuli, Sarah and Bruno, Ximena Jordan and Carroll, Martin P and Freyer, Craig W and Carulli, Alison and Babushok, Daria V and Frey, Noelle V and Hexner, Elizabeth O and Martin, Mary Ellen and McCurdy, Shannon R and Stadtmauer, Edward A and Loren, Alison W and Paralkar, Vikram R and Maillard, Ivan P and Pratz, Keith W},
title = {Real‐world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia},
journal = {American Journal of Hematology},
year = {2023},
volume = {98},
number = {8},
pages = {1254--1264},
doi = {10.1002/ajh.26991}
}
EUVIMED